Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Beigene Ltd ADR
(NQ:
BGNE
)
160.93
+6.19 (+4.00%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Beigene Ltd ADR
< Previous
1
2
3
4
5
6
7
Next >
BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for BRUKINSA® Versus IMBRUVICA® in Late-Breaking Oral Session at ASH 2022
November 22, 2022
From
BeiGene
Via
Business Wire
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Chronic Lymphocytic Leukemia (CLL)
November 17, 2022
From
BeiGene
Via
Business Wire
BeiGene Launches Talk About It Program to Elevate the Importance of Addressing Mental Health during Cancer Care
November 15, 2022
From
BeiGene
Via
Business Wire
BeiGene Announces Brazil Approvals for BRUKINSA® As a Treatment for Rare Blood Cancers
November 10, 2022
From
BeiGene
Via
Business Wire
BeiGene Reports Third Quarter 2022 Financial Results
November 09, 2022
From
BeiGene, Ltd.
Via
Business Wire
BeiGene to Present at Upcoming Investor Conferences
November 04, 2022
From
BeiGene
Via
Business Wire
BeiGene to Present Dynamic View of Development Programs for Hematologic Malignancies at 64th ASH Meeting
November 03, 2022
From
BeiGene
Via
Business Wire
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma
November 02, 2022
From
BeiGene
Via
Business Wire
BeiGene Expands Reach of its Innovative BTK Inhibitor with Recent Regulatory Approvals in Latin America
October 26, 2022
From
BeiGene
Via
Business Wire
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults With CLL
October 14, 2022
From
BeiGene
Via
Business Wire
BeiGene Announces Positive Topline Results from Final Progression-Free Survival Analysis of BRUKINSA® (zanubrutinib) Compared to IMBRUVICA® (ibrutinib) in Phase 3 Chronic Lymphocytic Leukemia (CLL) Trial
October 12, 2022
From
BeiGene
Via
Business Wire
NICE Recommends BeiGene’s BRUKINSA® (zanubrutinib) for Patients with Waldenström’s Macroglobulinemia who have had at Least One Treatment
September 19, 2022
From
BeiGene
Via
Business Wire
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma
September 19, 2022
From
BeiGene
Via
Business Wire
BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presentation for Tislelizumab in First-Line Unresectable Hepatocellular Cancer
September 10, 2022
From
BeiGene
Via
Business Wire
BeiGene to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
September 07, 2022
From
BeiGene
Via
Business Wire
BeiGene Announces Acceptance of 11th Regulatory Submission for PD-1 Inhibitor Tislelizumab in China
August 23, 2022
From
BeiGene
Via
Business Wire
BeiGene Announces Strategic Alliance with Ontada to Improve U.S. Community Oncology Care
August 15, 2022
From
BeiGene
Via
Business Wire
BeiGene Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab in First-Line Unresectable Hepatocellular Cancer
August 09, 2022
From
BeiGene
Via
Business Wire
BeiGene Reports Second Quarter 2022 Financial Results
August 04, 2022
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Provides Regulatory Update on the U.S. Biologics License Application (BLA) for PD-1 Inhibitor Tislelizumab in 2L ESCC
July 14, 2022
From
BeiGene
Via
Business Wire
BeiGene Appoints Chan Lee as General Counsel
July 13, 2022
From
BeiGene
Via
Business Wire
BeiGene Announces Strategic Research Collaboration with InnoRNA to Jointly Discover Novel mRNA Therapies
July 06, 2022
From
BeiGene
Via
Business Wire
BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tislelizumab Plus Chemotherapy in First-Line Advanced or Metastatic Esophageal Squamous Cell Carcinoma
June 30, 2022
From
BeiGene
Via
Business Wire
BeiGene Announces Acceptance of Supplemental Biologics License Application in China for Anti-PD-1 Inhibitor Tislelizumab
June 21, 2022
From
BeiGene
Via
Business Wire
BeiGene Announces BRUKINSA™ (zanubrutinib) Is Approved in 50 Markets
June 13, 2022
From
BeiGene
Via
Business Wire
BeiGene Announces PDUFA Goal Date Extension for U.S. sNDA for BRUKINSA for the Treatment of CLL/SLL
June 13, 2022
From
BeiGene
Via
Business Wire
BeiGene Highlights Growing Portfolio and Pipeline Targeting Hematologic Malignancies at European Hematology Association 2022 Congress
June 10, 2022
From
BeiGene
Via
Business Wire
China NMPA Approves Tislelizumab for Recurrent or Metastatic Nasopharyngeal Cancer
June 10, 2022
From
BeiGene
Via
Business Wire
BeiGene to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
June 08, 2022
From
BeiGene
Via
Business Wire
BeiGene Clinical Data Presentations at 2022 ASCO Annual Meeting Demonstrate Mature and Growing Oncology Portfolio
May 26, 2022
From
BeiGene
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.